Charles retweeted
#Anteristech announces powerful new data from the DurAVR™ THV FIH Study demonstrating sustained haemodynamic performance at 1 year in 12 patients. #TAVR $AVR #TAVI #cardiology #AnterisTech
Read Full Announcement: links.anteristech.com/3MVmdN…
Charles retweeted
Is this the next breakthrough in tissue #TAVR? Congrats @chrismeduri @bapat_savrtavr @SusheelKodaliMD @psorajja on DurAVR 1y data @PCRonline #PCR2023 @EuroInterventio look fwd to EFS! @mirvatalasnag @igeorge1975 @didier_tchetche @djc795 @modine_thomas @esaadi @TsuyoshiKaneko1
The DurAVR transcatheter heart valve was evaluated in a first-in-human study for treating symptomatic severe aortic stenosis. The study demonstrated a good safety profile and promising haemodynamic performance sustained at 1 year. #EAPCI #EUROPCR ow.ly/Lvya50OsBmL
Charles retweeted
#Anteristech announces #DurAVR™ Transcatheter Heart Valve (THV) Aortic Stenosis First-in-Human Study results. All performance endpoints met with remarkable hemodynamic function sustained at 12 months.
Full Announcement: ow.ly/CU5h50MrjG6 $AVR #TAVI #TAVR #cardiology
Charles retweeted
#Anteristech CMO @chrismeduri presented Late Breaking Clinical Trial at #PCVLV to a packed audience. At the same time, DurAVR has been approved by the FDA for EFS study. Incredible collaboration by world #TAVR #TAVI authorities pioneering new technology. #proudtobeanteris $AVR
Charles retweeted
Thought provoking #DurAVR BEV #TAVR with 1 piece tissue showing laminar flow in aorta #CMR and large EOA low gradient. Does design & leaflet motion matter? Look fwd to more clinical data. @TCTConference #TCT2022 @chrismeduri @GAilawadiMD @bapat_savrtavr @JoaoLCavalcante @KHERA_MD
#durAVR V Bapat @MHIF_Heart @JoaoLCavalcante
1st AVR to demonstrate restoration of normal flow dynamics ,safe & feasible even in pts w small annulus @rajdoc2005 @adnanalkhouli @JudyHungMD @JGrapsa @purviparwani @hahn_rt @sarano_maurice @mmamas1973 @TCTMD @renujain19 @ASE360









